Novel piperazine–chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation

References

• Varmus H. The new era in cancer research. Science 2006;312:1162–5.
   PubMed Web of Science ®Google Scholar
• Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287:1969–73.
   PubMed Web of Science ®Google Scholar
• Kerru N, Singh P, Koorbanally N, et al. Recent advances (2015–2016) in anticancer hybrids. Eur J Med Chem 2017;142:179–212.
   PubMed Web of Science ®Google Scholar
• Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Phys 2008;77:311–9.
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505–15.
   PubMed Web of Science ®Google Scholar
• Polverini PJ. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995;6:230–47.
   PubMedGoogle Scholar
• Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009;19:329–37.
   PubMed Web of Science ®Google Scholar
• Fidler IJ. Angiogenesis and cancer metastasis. Cancer J 2000;6:S134–S41.
   PubMed Web of Science ®Google Scholar
• Shawver LK, Lipson KE, Fong TAT, et al. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov Today 1997;2:50–63.
   Web of Science ®Google Scholar
• Traxler P. Tyrosine kinases as targets in cancer therapy – successes and failures. Expert Opin Ther Targets 2003;7:215–34.
   PubMed Web of Science ®Google Scholar
• Abhinand CS, Raju R, Soumya SJ, et al. VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. J Cell Commun Signal 2016;10:347–54.
   PubMed Web of Science ®Google Scholar
• Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549–80.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611.
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, et al. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21:154–65.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2:1097–105.
   PubMedGoogle Scholar
• Daniel JE, La S, Julie B, et al. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J Med Chem 2008;51:1695–705.
   PubMed Web of Science ®Google Scholar
• Machado VA, Peixoto D, Costa R, et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497–509.
   PubMed Web of Science ®Google Scholar
• Rajagopalan M, Balasubramanian S, Ramaswamy A, et al. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors. J Enzyme Inhib Med Chem 2013;28:1236–46.
   PubMed Web of Science ®Google Scholar
• Elsayed NMY, Serya RAT, Tolba MF, et al. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. Bioorg Chem 2019;82:340–59.
   PubMed Web of Science ®Google Scholar
• Muresan-Pop M, Chereches G, Borodi G, et al. Structural characterization of 5-fluorouracil & piperazine new solid forms and evaluation of their antitumor activity. J Mol Struct 2020;1207:127842.
   Web of Science ®Google Scholar
• Mao ZW, Zheng X, Lin YP, et al. Design, synthesis and anticancer activity of novel hybrid compounds between benzofuran and N-aryl piperazine. Bioorg Med Chem Lett 2016;26:3421–4.
   PubMed Web of Science ®Google Scholar
• Patel RV, Mistry B, Syed R, et al. Chrysin–piperazine conjugates as antioxidant and anticancer agents. Eur J Pharm Sci 2016;88:166–77.
   PubMed Web of Science ®Google Scholar
• Mehtap T, Halise IG, Kenjiro B, et al. Synthesis and biological evaluation of some new mono Mannich bases with piperazines as possible anticancer agents and carbonic anhydrase inhibitors. Bioorg Chem 2019;90:103095.
   PubMed Web of Science ®Google Scholar
• Gokhan-Kelekci N, Yabanoglu S, Kupeli E, et al. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and anti-inflammatory analgesics. Bioorg Med Chem 2007;15:5775–86.
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz M, Abuo-Rahma GA, Hassan AA. Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities. Eur J Med Chem 2009;44:3480–7.
   PubMed Web of Science ®Google Scholar
• Kaushik D, Khan SA, Chawla G, et al. N′-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene] 2/4-substituted hydrazides: synthesis and anticonvulsant activity. Eur J Med Chem 2010;45:3943–9.
   PubMed Web of Science ®Google Scholar
• Khunt RC, Khedkar VM, Chawda RS, et al. Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives. Bioorg Med Chem Lett 2012;22:666–78.
   PubMed Web of Science ®Google Scholar
• Pathak RB, Chovatia PT, Parekh HH. Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Bioorg Med Chem Lett 2012;22:5129–33.
   PubMed Web of Science ®Google Scholar
• Malladi S, Isloor AM, Peethambar SK, et al. Synthesis and antimicrobial activity of some new pyrazole containing cyanopyridone derivatives. Der Pharm Chem 2012;4:43–52.
   Google Scholar
• Puthran D, Poojary B, Purushotham N, et al. Synthesis of novel Schiff bases using 2-amino-5-(3-fluoro-4-methoxyphenyl)thiophene-3-carbonitrile and 1,3-disubstituted pyrazole-4-carboxaldehydes derivatives and their antimicrobial activity. Heliyon 2019;5:e02233.
   PubMed Web of Science ®Google Scholar
• Vijesh AM, Isloor AM, Shetty P, et al. New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents. Eur J Med Chem 2013;62:410–5.
   PubMed Web of Science ®Google Scholar
• Zabiulla GA, Mohammed YHE, et al. Design, synthesis and molecular docking of benzophenone conjugated with oxadiazole sulphur bridge pyrazole pharmacophores as anti-inflammatory and analgesic agents. Bioorg Chem 2019;92:103220.
   PubMed Web of Science ®Google Scholar
• Koca İ, Özgür A, Coşkun KA, et al. Synthesis and anticancer activity of acyl thioureas bearing pyrazole moiety. Bioorg Med Chem 2013;21:3859–65.
   PubMed Web of Science ®Google Scholar
• Abdellatif KR, Abdelall EK, Abdelgawad MA, et al. Synthesis and anticancer activity of some new pyrazolo[3,4-d]pyrimidin-4-one derivatives. Molecules 2014;19:3297–309.
   PubMed Web of Science ®Google Scholar
• Dawood KM, Eldebss TMA, El-Zahabi HSA, et al. Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents. Eur J Med Chem 2013;70:740–9.
   PubMed Web of Science ®Google Scholar
• Tu CH, Lin WH, Peng YH, et al. Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK). J Med Chem 2016;59:3906–19.
   PubMed Web of Science ®Google Scholar
• Thomas R, Mary YS, Resmi KS, et al. Two neoteric pyrazole compounds as potential anti-cancer agents: synthesis, electronic structure, physico-chemical properties and docking analysis. J Mol Struct 2019;1181:455–66.
   Web of Science ®Google Scholar
• Bennani FE, Doudach L, Cherrah Y, et al. Overview of recent developments of pyrazole derivatives as an anticancer agent in different cell line. Bioorg Chem 2020;97:103470–62.
   PubMed Web of Science ®Google Scholar
• Farooqui AA. Phytochemicals, signal transduction, and neurological disorders. New York, USA: Springer Science & Business Media; 2012.
   Google Scholar
• Mahapatra DK, Asati V, Bharti SK. Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. Eur J Med Chem 2015;92:839–65.
   PubMed Web of Science ®Google Scholar
• Israf DA, Khaizurin TA, Syahida A, et al. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kB nuclear translocation and Ik-B phosphorylation in RAW 264.7 macrophage cells. Mol Immunol 2007;44:673–9.
   PubMed Web of Science ®Google Scholar
• Kantevari S, Addla D, Bagul PK, et al. Synthesis and evaluation of novel 2-butyl-4-chloro-1-methylimidazole embedded chalcones and pyrazoles as angiotensin converting enzyme (ACE) inhibitors. Bioorg Med Chem 2011;19:4772–81.
   PubMed Web of Science ®Google Scholar
• Romagnolo DF, Selmin OI. Flavonoids and cancer prevention: a review of the evidence. J Nutr Gerontol Geriatr 2012;31:206–38.
   PubMedGoogle Scholar
• Chen M, Brøgger CS, Zhai L, et al. The novel oxygenated chalcone, 2,4-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J Infect Dis 1997;176:1327–33.
   PubMed Web of Science ®Google Scholar
• Winter E, Gozzi GJ, Chiaradia-Delatorre LD, et al. Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position. Drug Des Dev Ther 2014;8:609–19.
   PubMed Web of Science ®Google Scholar
• Debarshi KM, Sanjay KB, Vivek A. Anti-cancer chalcones: structural and molecular target perspectives. Eur J Med Chem 2015;98:69–114.
   PubMed Web of Science ®Google Scholar
• Lee YS, Lim SS, Shin KM, et al. Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′-methoxychalcone. Biol Pharm Bull 2006;29:1028–31.
   PubMed Web of Science ®Google Scholar
• Varinska L, Wijhe M, Belleri M, et al. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. Eur J Pharmacol 2012;691:125–33.
   PubMed Web of Science ®Google Scholar
• Guo F, Feng L, Huang C, et al. Prenylflavone derivatives from Broussonetia papyrifera, inhibit the growth of breast cancer cells in vitro and in vivo. Phytochem Lett 2013;6:331–6.
   Web of Science ®Google Scholar
• Sisko JT, Tucker TJ, Bilodeau MT, et al. Potent 2-[(pyrimidin-4-yl)amine]-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett 2006;16:1146–50.
   PubMed Web of Science ®Google Scholar
• Peng F-W, Liu D-K, Zhang Q-W, et al. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012–2016). Expert Opin Ther Pat 2017;27:987–1004.
   PubMed Web of Science ®Google Scholar
• Mainolfi N, Karki R, Liu F, Anderson K. Evolution of a new class of VEGFR-2 inhibitors from scaffold morphing and redesign. ACS Med Chem Lett 2016;7:363–7.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Miyamoto N, Hirayama T, et al. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Bioorg Med Chem 2013;21:7686–98.
   PubMedGoogle Scholar
• Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci 2003;94:751–6.
   PubMed Web of Science ®Google Scholar
• Sun YS. Cancer Center, South China Institute of Botany, Chinese Academy of Sciences Assignee. Use of 20,40 dihydroxy-60-methoxy-30,50 dimethyl-chalcone for preparing anticancer medicine, Patent CN1454895 A; 2003.
   Google Scholar
• Rizvi SUF, Siddiqui HL, Nisar M, et al. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase. Bioorg Med Chem Lett 2012;22:942–4.
   PubMed Web of Science ®Google Scholar
• Molecular operating environment (MOE), 10. Montreal: Chemical Computing Group Inc.; 2009.
   Google Scholar
• Ibrahim MK, Taghour MS, Metwaly AM, et al. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors. Eur J Med Chem 2018;155:117–34.
   PubMed Web of Science ®Google Scholar
• DTP selection guidelines; 2020. Available from: https://dtp.cancer.gov/organization/dscb/compoundSubmission/structureSelection.htm.
   Google Scholar
• Liu F, Dawadi S, Maize KM, et al. Structure-based optimization of pyridoxal 5′-phosphate-dependent transaminase enzyme (BioA) inhibitors that target biotin biosynthesis in Mycobacterium tuberculosis. J Med Chem 2017;60:5507–20.
   PubMed Web of Science ®Google Scholar
• Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–66.
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000;113:753–7.
   PubMed Web of Science ®Google Scholar
• Lo KKW, Lee TKM, Lau JSY, et al. Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes. Inorg Chem 2008;47:200–8.
   PubMed Web of Science ®Google Scholar